MORGANTOWN, W.V., June 12, 2014 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) ("Protea") announced today that it will be attending the American Society of Mass Spectrometry Annual Conference in Baltimore, MD. The Conference will take place at the Baltimore Convention Center, located at 1 West Pratt Street, Baltimore, MD 21201 from Sunday June 15th through Thursday June 19th.
"We are very much looking forward to ASMS this year as it will be our largest presence at the annual conference yet," stated Stephen Turner, Protea's CEO. He continued, "This year Protea will be presenting ten posters, one oral presentation and hosting a breakfast seminar with a scientist from the University of Oklahoma. In addition, we will have an exhibit booth and hospitality suite where conference attendees can meet with our staff and learn more about our technologies and offerings."
"We offer our clients' access to an exceptional portfolio of state-of-the-art mass spectrometry based imaging and LC-MS bioanalytical services," said Dr. Greg Kilby, Protea's Director of Molecular Imaging and Bioanalytical Services. "We are pushing the envelope in the development and application of mass spectrometry imaging, exploring synergies between LAESI and MALDI imaging and complementary LC-MS technologies. At this year's ASMS conference, we will be presenting some key examples of this work, such as using Protea acid cleavable detergents to enhance MALDI protein imaging, and high throughput LAESI-MS fungal metabolite profiling using high resolution accurate mass spectrometry."
Details about Protea's ASMS presence can be found below or through the following link https://proteabio.com/ASMS2014/scientific+program:
| Protea Exhibition Booth |
| Booth #46, June 15th – 19th, Exhibit Halls C - G |
| Baltimore Convention Center, 1 W Pratt Street, Baltimore, MD 21201 |
| Poster Presentations - Protea's Scientific Program |
| Exhibit Halls C - G, June 16th - 19th, 10:30am – 2:30pm EDT |
| Baltimore Convention Center, 1 W Pratt Street, Baltimore, MD 21201 |
| Hospitality Suite |
| Pickersgill Suite, June 16th – 18th, 8:00pm – 11:00pm EDT |
| Hilton Baltimore, 401 W Pratt Street, Baltimore, MD 21201 |
| Breakfast Seminar |
| Direct, rapid profiling and screening of fungal, bacterial colonies and extracts for natural product discovery with the LAESI DP-1000 system |
| Register Now |
| Wednesday, June 18th - 7:00am – 8:00am EDT |
| Room 328, Baltimore Convention Center |
| 1 W Pratt Street, Baltimore, MD 21201 |
About Protea Biosciences Group, Inc.
Protea Biosciences (OTCQB:PRGB) is a commercial stage molecular information company, focused on meeting the needs of the pharmaceutical, biotechnology, agricultural, chemical and other industries with innovative bioanalytical technologies. Protea's proprietary technology, LAESI® (Laser Ablation Electrospray Ionization), is used with mass spectrometry to identify large numbers of distinct molecules from a single analysis of tissues, cells, fluids, agricultural specimens and other sample types. Using proprietary software (ProteaPlot™), the location of each distinct molecule in a respective sample can be displayed, enabling direct molecular imaging. The LAESI DP-1000, an integrated system that combines LAESI and ProteaPlot, is marketed to a wide array of researchers for numerous applications. Protea maintains its own laboratory facility where it performs services using LAESI and complementary technologies for a wide array of customers to support preclinical pharmaceutical R&D, biomarker discovery and other applications. Protea also collaborates with researchers to apply its technologies and expertise toward new discovery and technology development.
https://proteabio.com/investors
Forward-Looking Statements
This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further information concerning the Company and its business, including factors that potentially could materially affect the Company's financial results, are contained in the Company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
For more Information:
Protea Biosciences Group, Inc., 955 Hartman Run Road, Morgantown, WV 26507 USA
Phone: 304.292.2226 Fax: 304.292.7101
steve.oloughlin@proteabio.com
Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.